{"url_path":"/sec/elox/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1035354/0001193125-26-345032-index.html","accession_number":"0001193125-26-345032","cik":"0001035354","ticker":"ELOX","issuer_name":"Eloxx Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1035354/0001193125-26-345032-index.html","primary_entity_key":"0001035354","primary_entity_name":"Eloxx Pharmaceuticals, Inc."},"word_count":172,"has_tables":true,"body_markdown":"Item 2.02.\n\nResults of Operations and Financial Condition.\n\nOn August 11, 2026, Eloxx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026 and providing a business update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing."}